Daiwa Securities Group Inc. Adaptimmune Therapeutics PLC Transaction History

Daiwa Securities Group Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$1.06 - $2.41 $19,513 - $44,365	-18,409 Reduced 97.52%	469 $1,000
Q2 2022 Aug 09, 2022	SELL	$1.33 - $2.28 $22,128 - $37,934	-16,638 Reduced 46.85%	18,878 $32,000
Q1 2022 Apr 29, 2022	BUY	$1.73 - $4.06 $19,031 - $44,664	11,001 Added 44.87%	35,516 $73,000
Q4 2021 Feb 03, 2022	BUY	$3.5 - $5.68 $31,965 - $51,875	9,133 Added 59.37%	24,515 $92,000
Q3 2021 Nov 05, 2021	BUY	$3.44 - $6.37 $52,033 - $96,352	15,126 Added 5908.59%	15,382 $80,000
Q4 2020 Feb 04, 2021	BUY	$4.0 - $9.2 $1,024 - $2,355	256 New	256 $1,000
Q4 2019 Jan 31, 2020	SELL	$0.72 - $1.43 $232 - $461	-323 Closed	0 $0
Q1 2018 May 02, 2018	BUY	$7.1 - $11.56 $2,293 - $3,733	323 New	323 $4,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $105M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.